Gan & Lee(SH:603087) Xin Lang Cai Jing·2025-10-31 06:30Core Insights - The company reported significant growth in revenue and net profit for the first three quarters of 2025, with revenue reaching 3.047 billion yuan and net profit at 818 million yuan, representing year-on-year increases of 35.73% and 61.32% respectively [1][2]. Group 1: Revenue Growth - Domestic sales revenue for the first three quarters of 2025 was 2.690 billion yuan, up 44.01%, while international sales revenue was 353 million yuan, up 45.52% [2]. - The growth in revenue is attributed to the price increase following the continuation of domestic insulin procurement and the expansion of international market sales [2][3]. Group 2: Domestic Sales Performance - Domestic insulin formulation revenue reached 2.624 billion yuan, reflecting a year-on-year growth of 45.6%, with volume contributing 27.3% and price contributing 18.3% to this growth [3]. Group 3: Global Strategy - The company is actively pursuing a global strategy, resulting in high growth in international sales, including a 10-year technical transfer and supply agreement with Brazil, with a total order value of no less than 3 billion yuan [4]. Group 4: R&D Pipeline - The company is advancing its insulin weekly formulation, which is expected to become a cornerstone drug for diabetes treatment globally, with several projects in clinical trials progressing well [5]. Group 5: Investment Outlook - The company forecasts net profits of 1.109 billion yuan, 1.432 billion yuan, and 1.595 billion yuan for 2025 to 2027, with respective year-on-year growth rates of 80.4%, 29.1%, and 11.4% [6].